Skip to main content
Top
Published in: Japanese Journal of Radiology 6/2023

21-01-2023 | Magnetic Resonance Imaging | Invited Review

Imaging of metabolic and overload disorders in tissues and organs

Authors: Federico Bruno, Domenico Albano, Andrea Agostini, Massimo Benenati, Roberto Cannella, Damiano Caruso, Michaela Cellina, Diletta Cozzi, Ginevra Danti, Federica De Muzio, Francesco Gentili, Giuliana Giacobbe, Salvatore Gitto, Giulia Grazzini, Irene Grazzini, Carmelo Messina, Anna Palmisano, Pierpaolo Palumbo, Alessandra Bruno, Francesca Grassi, Roberta Grassi, Roberta Fusco, Vincenza Granata, Andrea Giovagnoni, Vittorio Miele, Antonio Barile, on behalf of the Young SIRM Working Group

Published in: Japanese Journal of Radiology | Issue 6/2023

Login to get access

Abstract

Metabolic and overload disorders are a heterogeneous group of relatively uncommon but important diseases. While imaging plays a key role in the early detection and accurate diagnosis in specific organs with a pivotal role in several metabolic pathways, most of these diseases affect different tissues as part of a systemic syndromes. Moreover, since the symptoms are often vague and phenotypes similar, imaging alterations can present as incidental findings, which must be recognized and interpreted in the light of further biochemical and histological investigations. Among imaging modalities, MRI allows, thanks to its multiparametric properties, to obtain numerous information on tissue composition, but many metabolic and accumulation alterations require a multimodal evaluation, possibly using advanced imaging techniques and sequences, not only for the detection but also for accurate characterization and quantification. The purpose of this review is to describe the different alterations resulting from metabolic and overload pathologies in organs and tissues throughout the body, with particular reference to imaging findings.
Literature
1.
go back to reference Ferreira CR, Martinelli D, Blau N. Clinical and biochemical footprints of inherited metabolic diseases VI. Metabolic dermatoses. Mol Genet Metab. 2021;134(1–2):87–95.PubMedPubMedCentralCrossRef Ferreira CR, Martinelli D, Blau N. Clinical and biochemical footprints of inherited metabolic diseases VI. Metabolic dermatoses. Mol Genet Metab. 2021;134(1–2):87–95.PubMedPubMedCentralCrossRef
2.
go back to reference Lagergren K, Wahlin K, Mattsson F, Alderson D, Lagergren J. Haemochromatosis and gastrointestinal cancer. Int J Cancer. 2016;139(8):1740–3.PubMedCrossRef Lagergren K, Wahlin K, Mattsson F, Alderson D, Lagergren J. Haemochromatosis and gastrointestinal cancer. Int J Cancer. 2016;139(8):1740–3.PubMedCrossRef
4.
go back to reference Messina C, Albano D, Gitto S, Tofanelli L, Bazzocchi A, Ulivieri FM, et al. Body composition with dual energy X-ray absorptiometry: from basics to new tools. Quant Imaging Med Surg. 2020;10(8):1687–98.PubMedPubMedCentralCrossRef Messina C, Albano D, Gitto S, Tofanelli L, Bazzocchi A, Ulivieri FM, et al. Body composition with dual energy X-ray absorptiometry: from basics to new tools. Quant Imaging Med Surg. 2020;10(8):1687–98.PubMedPubMedCentralCrossRef
5.
go back to reference Albano D, Messina C, Vitale J, Sconfienza LM. Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2020;30(4):2199–208.PubMedCrossRef Albano D, Messina C, Vitale J, Sconfienza LM. Imaging of sarcopenia: old evidence and new insights. Eur Radiol. 2020;30(4):2199–208.PubMedCrossRef
6.
7.
go back to reference Queiroz-Andrade M, Blasbalg R, Ortega CD, Rodstein MA, Baroni RH, Rocha MS, et al. MR imaging findings of iron overload. Radiographics. 2009;29(6):1575–89.PubMedCrossRef Queiroz-Andrade M, Blasbalg R, Ortega CD, Rodstein MA, Baroni RH, Rocha MS, et al. MR imaging findings of iron overload. Radiographics. 2009;29(6):1575–89.PubMedCrossRef
8.
go back to reference Chung MJ, Lee KS, Franquet T, Muller NL, Han J, Kwon OJ. Metabolic lung disease: imaging and histopathologic findings. Eur J Radiol. 2005;54(2):233–45.PubMedCrossRef Chung MJ, Lee KS, Franquet T, Muller NL, Han J, Kwon OJ. Metabolic lung disease: imaging and histopathologic findings. Eur J Radiol. 2005;54(2):233–45.PubMedCrossRef
9.
go back to reference de Oliveira AM, Paulino MV, Vieira APF, McKinney AM, da Rocha AJ, Dos Santos GT, et al. Imaging patterns of toxic and metabolic brain disorders. Radiographics. 2019;39(6):1672–95.PubMedCrossRef de Oliveira AM, Paulino MV, Vieira APF, McKinney AM, da Rocha AJ, Dos Santos GT, et al. Imaging patterns of toxic and metabolic brain disorders. Radiographics. 2019;39(6):1672–95.PubMedCrossRef
10.
go back to reference Bordonaro V, Ciancarella P, Ciliberti P, Curione D, Napolitano C, Santangelo TP, et al. Dynamic contrast-enhanced magnetic resonance lymphangiography in pediatric patients with central lymphatic system disorders. Radiol Med. 2021;126(5):737–43.PubMedCrossRef Bordonaro V, Ciancarella P, Ciliberti P, Curione D, Napolitano C, Santangelo TP, et al. Dynamic contrast-enhanced magnetic resonance lymphangiography in pediatric patients with central lymphatic system disorders. Radiol Med. 2021;126(5):737–43.PubMedCrossRef
11.
go back to reference Jafari SH, Haseli S, Kaffashan S, Saeedi-Moghadam M, Iranpour P, Zeinali-Rafsanjani B. Assessment of the Hallmarks of Wilson disease in CT scan imaging. J Med Imaging Radiat Sci. 2020;51(1):145–53.PubMedCrossRef Jafari SH, Haseli S, Kaffashan S, Saeedi-Moghadam M, Iranpour P, Zeinali-Rafsanjani B. Assessment of the Hallmarks of Wilson disease in CT scan imaging. J Med Imaging Radiat Sci. 2020;51(1):145–53.PubMedCrossRef
12.
go back to reference Amin K, Mileto A, Kolokythas O. MRI for liver iron quantification: concepts and current methods. Semin Ultrasound CT MR. 2022;43(4):364–70.PubMedCrossRef Amin K, Mileto A, Kolokythas O. MRI for liver iron quantification: concepts and current methods. Semin Ultrasound CT MR. 2022;43(4):364–70.PubMedCrossRef
13.
go back to reference Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637–53.PubMedCrossRef Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637–53.PubMedCrossRef
14.
go back to reference Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, et al. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr. 2004;28(2):158–68.PubMedCrossRef Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, et al. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr. 2004;28(2):158–68.PubMedCrossRef
17.
go back to reference Paoletti M, Muzic SI, Marchetti F, Farina LM, Bastianello S, Pichiecchio A. Differential imaging of atypical demyelinating lesions of the central nervous system. Radiologia Medica. 2021;126(6):827–42.PubMedCrossRef Paoletti M, Muzic SI, Marchetti F, Farina LM, Bastianello S, Pichiecchio A. Differential imaging of atypical demyelinating lesions of the central nervous system. Radiologia Medica. 2021;126(6):827–42.PubMedCrossRef
18.
go back to reference Santos Andrade C, Tavares Lucato L, Da Martin MGM, Marques-Dias MJ, Portela LAP, Gattas GS, et al. Non-alcoholic Wernicke’s encephalopathy: broadening the clinicoradiological spectrum. Br J Radiol. 2010;83(989):437–46.PubMedPubMedCentralCrossRef Santos Andrade C, Tavares Lucato L, Da Martin MGM, Marques-Dias MJ, Portela LAP, Gattas GS, et al. Non-alcoholic Wernicke’s encephalopathy: broadening the clinicoradiological spectrum. Br J Radiol. 2010;83(989):437–46.PubMedPubMedCentralCrossRef
19.
go back to reference Kim TE, Lee EJ, Young JB, Shin DJ, Kim JH. Wernicke encephalopathy and ethanol-related syndromes. Semin Ultrasound CT MR. 2014;35(2):85–96.PubMedCrossRef Kim TE, Lee EJ, Young JB, Shin DJ, Kim JH. Wernicke encephalopathy and ethanol-related syndromes. Semin Ultrasound CT MR. 2014;35(2):85–96.PubMedCrossRef
21.
go back to reference Kumar G, Goyal MK. Lentiform Fork sign: a unique MRI picture. Is metabolic acidosis responsible? Clin Neurol Neurosurg. 2010;112(9):805–12.PubMedCrossRef Kumar G, Goyal MK. Lentiform Fork sign: a unique MRI picture. Is metabolic acidosis responsible? Clin Neurol Neurosurg. 2010;112(9):805–12.PubMedCrossRef
24.
go back to reference Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300–12.PubMedCrossRef Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300–12.PubMedCrossRef
26.
go back to reference Choi JW, Moon WJ. Gadolinium deposition in the brain: current updates. Korean J Radiol. 2019;20(1):134–47.PubMedCrossRef Choi JW, Moon WJ. Gadolinium deposition in the brain: current updates. Korean J Radiol. 2019;20(1):134–47.PubMedCrossRef
27.
go back to reference Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. AJR Am J Roentgenol. 2009;193(3):879–86.PubMedCrossRef Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. AJR Am J Roentgenol. 2009;193(3):879–86.PubMedCrossRef
28.
go back to reference Uk-I JM, Yu E, Bartlett E, Soobrah R, Kucharczyk W. Acute hyperammonemic encephalopathy in adults: imaging findings. AJNR Am J Neuroradiol. 2011;32(2):413–8.CrossRef Uk-I JM, Yu E, Bartlett E, Soobrah R, Kucharczyk W. Acute hyperammonemic encephalopathy in adults: imaging findings. AJNR Am J Neuroradiol. 2011;32(2):413–8.CrossRef
29.
go back to reference Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D, et al. Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. Insights Imaging. 2021;12(1):76.PubMedPubMedCentralCrossRef Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D, et al. Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. Insights Imaging. 2021;12(1):76.PubMedPubMedCentralCrossRef
30.
go back to reference McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol. 2009;193(1):192–206.PubMedCrossRef McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L. Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol. 2009;193(1):192–206.PubMedCrossRef
31.
go back to reference Sahu A, Sankhe S, Mittal K, Kamath N, Pg N, Sahu A. A pictorial review on reversible splenial lesions. Indian J Radiol Imaging. 2021;31(1):3–9.PubMedPubMedCentral Sahu A, Sankhe S, Mittal K, Kamath N, Pg N, Sahu A. A pictorial review on reversible splenial lesions. Indian J Radiol Imaging. 2021;31(1):3–9.PubMedPubMedCentral
32.
go back to reference Bhatia S, Kapoor AK, Sharma A, Gupta R, Kataria S. Cerebral encephalopathy with extrapontine myelinolysis in a case of postpartum hypernatremia. Indian J Radiol Imaging. 2014;24(1):57–60.PubMedPubMedCentralCrossRef Bhatia S, Kapoor AK, Sharma A, Gupta R, Kataria S. Cerebral encephalopathy with extrapontine myelinolysis in a case of postpartum hypernatremia. Indian J Radiol Imaging. 2014;24(1):57–60.PubMedPubMedCentralCrossRef
34.
go back to reference Saroja AO, Naik KR, Mali RV, Kunam SR. “Wine Glass” sign in recurrent postpartum hypernatremic osmotic cerebral demyelination. Ann Indian Acad Neurol. 2013;16(1):106–10.PubMedPubMedCentralCrossRef Saroja AO, Naik KR, Mali RV, Kunam SR. “Wine Glass” sign in recurrent postpartum hypernatremic osmotic cerebral demyelination. Ann Indian Acad Neurol. 2013;16(1):106–10.PubMedPubMedCentralCrossRef
35.
go back to reference Kumar A, Singh AK. Teaching neuroimage: inverted V sign in subacute combined degeneration of spinal cord. Neurology. 2009;72(1): e4.PubMedCrossRef Kumar A, Singh AK. Teaching neuroimage: inverted V sign in subacute combined degeneration of spinal cord. Neurology. 2009;72(1): e4.PubMedCrossRef
36.
go back to reference Ravina B, Loevner LA, Bank W. MR findings in subacute combined degeneration of the spinal cord: a case of reversible cervical myelopathy. AJR Am J Roentgenol. 2000;174(3):863–5.PubMedCrossRef Ravina B, Loevner LA, Bank W. MR findings in subacute combined degeneration of the spinal cord: a case of reversible cervical myelopathy. AJR Am J Roentgenol. 2000;174(3):863–5.PubMedCrossRef
37.
go back to reference Turna O, Turna IF. Quantitative assessment of cervical spinal cord by diffusion tensor tractography in 3.0.T. Radiologia Medica. 2021;126(1):83–8.PubMedCrossRef Turna O, Turna IF. Quantitative assessment of cervical spinal cord by diffusion tensor tractography in 3.0.T. Radiologia Medica. 2021;126(1):83–8.PubMedCrossRef
38.
go back to reference Jung JB, Kim Y, Oh K, Kim SA, Doh JH, Oh HJ, et al. Subacute combined degeneration associated with vitamin E deficiency due to small bowel obstruction: a case report. Medicine (Baltimore). 2019;98(36): e17052.PubMedCrossRef Jung JB, Kim Y, Oh K, Kim SA, Doh JH, Oh HJ, et al. Subacute combined degeneration associated with vitamin E deficiency due to small bowel obstruction: a case report. Medicine (Baltimore). 2019;98(36): e17052.PubMedCrossRef
39.
go back to reference Galea N, Polizzi G, Gatti M, Cundari G, Figuera M, Faletti R. Cardiovascular magnetic resonance (CMR) in restrictive cardiomyopathies. Radiologia Medica. 2020;125(11):1072–86.PubMedCrossRef Galea N, Polizzi G, Gatti M, Cundari G, Figuera M, Faletti R. Cardiovascular magnetic resonance (CMR) in restrictive cardiomyopathies. Radiologia Medica. 2020;125(11):1072–86.PubMedCrossRef
40.
go back to reference Di Cesare E, Carerj S, Palmisano A, Carerj ML, Catapano F, Vignale D, et al. Multimodality imaging in chronic heart failure. Radiologia Medica. 2021;126(2):231–42.PubMedCrossRef Di Cesare E, Carerj S, Palmisano A, Carerj ML, Catapano F, Vignale D, et al. Multimodality imaging in chronic heart failure. Radiologia Medica. 2021;126(2):231–42.PubMedCrossRef
41.
go back to reference Pierpaolo P, Rolf S, Manuel BP, Davide C, Dresselaers T, Claus P, et al. Left ventricular global myocardial strain assessment: are CMR feature-tracking algorithms useful in the clinical setting? Radiol Med. 2020;125(5):444–50.PubMedCrossRef Pierpaolo P, Rolf S, Manuel BP, Davide C, Dresselaers T, Claus P, et al. Left ventricular global myocardial strain assessment: are CMR feature-tracking algorithms useful in the clinical setting? Radiol Med. 2020;125(5):444–50.PubMedCrossRef
42.
go back to reference Esposito A, Francone M, Andreini D, Buffa V, Cademartiri F, Carbone I, et al. SIRM-SIC appropriateness criteria for the use of Cardiac Computed Tomography. Part 1: Congenital heart diseases, primary prevention, risk assessment before surgery, suspected CAD in symptomatic patients, plaque and epicardial adipose tissue characterization, and functional assessment of stenosis. Radiologia Medica. 2021;126(9):1236–48.PubMedCrossRef Esposito A, Francone M, Andreini D, Buffa V, Cademartiri F, Carbone I, et al. SIRM-SIC appropriateness criteria for the use of Cardiac Computed Tomography. Part 1: Congenital heart diseases, primary prevention, risk assessment before surgery, suspected CAD in symptomatic patients, plaque and epicardial adipose tissue characterization, and functional assessment of stenosis. Radiologia Medica. 2021;126(9):1236–48.PubMedCrossRef
43.
go back to reference Esposito A, Gallone G, Palmisano A, Marchitelli L, Catapano F, Francone M. The current landscape of imaging recommendations in cardiovascular clinical guidelines: toward an imaging-guided precision medicine. Radiologia Medica. 2020;125(11):1013–23.PubMedCrossRef Esposito A, Gallone G, Palmisano A, Marchitelli L, Catapano F, Francone M. The current landscape of imaging recommendations in cardiovascular clinical guidelines: toward an imaging-guided precision medicine. Radiologia Medica. 2020;125(11):1013–23.PubMedCrossRef
44.
go back to reference Pontone G, Di Cesare E, Castelletti S, De Cobelli F, De Lazzari M, Esposito A, et al. Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SIC-SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart transplant). Radiologia Medica. 2021;126(3):365–79.PubMedCrossRef Pontone G, Di Cesare E, Castelletti S, De Cobelli F, De Lazzari M, Esposito A, et al. Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SIC-SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart transplant). Radiologia Medica. 2021;126(3):365–79.PubMedCrossRef
45.
go back to reference Pradella S, Grazzini G, De Amicis C, Letteriello M, Acquafresca M, Miele V. Cardiac magnetic resonance in hypertrophic and dilated cardiomyopathies. Radiologia Medica. 2020;125(11):1056–71.PubMedCrossRef Pradella S, Grazzini G, De Amicis C, Letteriello M, Acquafresca M, Miele V. Cardiac magnetic resonance in hypertrophic and dilated cardiomyopathies. Radiologia Medica. 2020;125(11):1056–71.PubMedCrossRef
46.
go back to reference Buffa V, Di Renzi P. CMR in the diagnosis of ischemic heart disease. Radiologia Medica. 2020;125(11):1114–23.PubMedCrossRef Buffa V, Di Renzi P. CMR in the diagnosis of ischemic heart disease. Radiologia Medica. 2020;125(11):1114–23.PubMedCrossRef
48.
go back to reference van Assen M, Muscogiuri G, Caruso D, Lee SJ, Laghi A, De Cecco CN. Artificial intelligence in cardiac radiology. Radiol Med. 2020;125(11):1186–99.PubMedCrossRef van Assen M, Muscogiuri G, Caruso D, Lee SJ, Laghi A, De Cecco CN. Artificial intelligence in cardiac radiology. Radiol Med. 2020;125(11):1186–99.PubMedCrossRef
49.
50.
go back to reference Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89.PubMedPubMedCentralCrossRef Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89.PubMedPubMedCentralCrossRef
51.
go back to reference Pierpaolo P, Rolf S, Manuel B-P, Davide C, Dresselaers T, Claus P, et al. Left ventricular global myocardial strain assessment: are CMR feature-tracking algorithms useful in the clinical setting? Radiologia Medica. 2020;125(5):444–50.PubMedCrossRef Pierpaolo P, Rolf S, Manuel B-P, Davide C, Dresselaers T, Claus P, et al. Left ventricular global myocardial strain assessment: are CMR feature-tracking algorithms useful in the clinical setting? Radiologia Medica. 2020;125(5):444–50.PubMedCrossRef
52.
go back to reference Palumbo P, Masedu F, De Cataldo C, Cannizzaro E, Bruno F, Pradella S, et al. Real-world clinical validity of cardiac magnetic resonance tissue tracking in primitive hypertrophic cardiomyopathy. Radiologia Medica. 2021;126(12):1532–43.PubMedCrossRef Palumbo P, Masedu F, De Cataldo C, Cannizzaro E, Bruno F, Pradella S, et al. Real-world clinical validity of cardiac magnetic resonance tissue tracking in primitive hypertrophic cardiomyopathy. Radiologia Medica. 2021;126(12):1532–43.PubMedCrossRef
53.
go back to reference Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77.PubMedPubMedCentralCrossRef Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77.PubMedPubMedCentralCrossRef
54.
go back to reference Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2018;25(4):215–9.PubMedCrossRef Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2018;25(4):215–9.PubMedCrossRef
55.
go back to reference Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–22.PubMedCrossRef Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–22.PubMedCrossRef
56.
go back to reference Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–91.PubMedPubMedCentralCrossRef Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–91.PubMedPubMedCentralCrossRef
57.
go back to reference Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.PubMedCrossRef Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.PubMedCrossRef
58.
go back to reference Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid. 2016;23(4):209–13.PubMedCrossRef Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid. 2016;23(4):209–13.PubMedCrossRef
59.
go back to reference Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1–39.PubMedCrossRef Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1–39.PubMedCrossRef
60.
go back to reference Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail. 2019;25(11):854–65.PubMedCrossRef Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail. 2019;25(11):854–65.PubMedCrossRef
61.
go back to reference Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065–123.PubMedCrossRef Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26(6):2065–123.PubMedCrossRef
62.
go back to reference Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27(2):659–73.PubMedCrossRef Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27(2):659–73.PubMedCrossRef
63.
64.
go back to reference Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512–26.PubMedCrossRef Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4):512–26.PubMedCrossRef
65.
go back to reference Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College Of Cardiology/American Heart Association Joint Committee on clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–80.PubMedCrossRef Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: a report of the American College Of Cardiology/American Heart Association Joint Committee on clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):1757–80.PubMedCrossRef
66.
go back to reference Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–421.PubMedCrossRef Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263–421.PubMedCrossRef
67.
go back to reference Russo V, Lovato L, Ligabue G. Cardiac MRI: technical basis. Radiologia Medica. 2020;125(11):1040–55.PubMedCrossRef Russo V, Lovato L, Ligabue G. Cardiac MRI: technical basis. Radiologia Medica. 2020;125(11):1040–55.PubMedCrossRef
68.
go back to reference Palmisano A, Darvizeh F, Cundari G, Rovere G, Ferrandino G, Nicoletti V, et al. Advanced cardiac imaging in athlete’s heart: unravelling the grey zone between physiologic adaptation and pathology. Radiologia Medica. 2021;126(12):1518–31.PubMedCrossRef Palmisano A, Darvizeh F, Cundari G, Rovere G, Ferrandino G, Nicoletti V, et al. Advanced cardiac imaging in athlete’s heart: unravelling the grey zone between physiologic adaptation and pathology. Radiologia Medica. 2021;126(12):1518–31.PubMedCrossRef
69.
go back to reference Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–9.PubMedCrossRef Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–9.PubMedCrossRef
70.
go back to reference Treibel TA, Kozor R, Menacho K, Castelletti S, Bulluck H, Rosmini S, et al. Left ventricular hypertrophy revisited: cell and matrix expansion have disease-specific relationships. Circulation. 2017;136(25):2519–21.PubMedCrossRef Treibel TA, Kozor R, Menacho K, Castelletti S, Bulluck H, Rosmini S, et al. Left ventricular hypertrophy revisited: cell and matrix expansion have disease-specific relationships. Circulation. 2017;136(25):2519–21.PubMedCrossRef
71.
go back to reference Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:129.PubMedPubMedCentralCrossRef Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:129.PubMedPubMedCentralCrossRef
72.
go back to reference Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919–31.PubMedCrossRef Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919–31.PubMedCrossRef
73.
go back to reference Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399–403.PubMedCrossRef Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007;50(25):2399–403.PubMedCrossRef
74.
go back to reference Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–38.PubMedCrossRef Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase a activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122–38.PubMedCrossRef
75.
go back to reference Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol. 2001;136:234–40.CrossRef Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol. 2001;136:234–40.CrossRef
76.
go back to reference Germain DP. Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs. 2002;11(10):1467–76.PubMedCrossRef Germain DP. Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs. 2002;11(10):1467–76.PubMedCrossRef
77.
go back to reference Germain DP. General aspects of X-linked diseases. In: Mehta AG, editor. Fabry Disease: Perspectives from 5 years of FOS. Oxford; 2006. Germain DP. General aspects of X-linked diseases. In: Mehta AG, editor. Fabry Disease: Perspectives from 5 years of FOS. Oxford; 2006.
80.
go back to reference Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease-a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224–35.PubMedCrossRef Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease-a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224–35.PubMedCrossRef
81.
go back to reference Germain DP, Benistan K, Angelova L. X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne. 2010;31(Suppl 2):S209–13.PubMedCrossRef Germain DP, Benistan K, Angelova L. X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne. 2010;31(Suppl 2):S209–13.PubMedCrossRef
82.
go back to reference Germain DP, Bruneval P, Tran TC, Balouet P, Richalet B, Benistan K. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report. Eur J Med Genet. 2010;53(2):111–2.PubMedCrossRef Germain DP, Bruneval P, Tran TC, Balouet P, Richalet B, Benistan K. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report. Eur J Med Genet. 2010;53(2):111–2.PubMedCrossRef
83.
go back to reference Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353–8.PubMedCrossRef Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353–8.PubMedCrossRef
84.
go back to reference Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19: 100454.PubMedPubMedCentralCrossRef Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19: 100454.PubMedPubMedCentralCrossRef
85.
go back to reference Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107–17.PubMedPubMedCentralCrossRef Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107–17.PubMedPubMedCentralCrossRef
86.
go back to reference Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7:91.PubMedPubMedCentralCrossRef Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7:91.PubMedPubMedCentralCrossRef
87.
go back to reference Germain DP, Levade T, Hachulla E, Knebelmann B, Lacombe D, Seguin VL, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101(4):390–402.PubMedCrossRef Germain DP, Levade T, Hachulla E, Knebelmann B, Lacombe D, Seguin VL, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101(4):390–402.PubMedCrossRef
88.
go back to reference Germain DP, Moiseev S, Suarez-Obando F, Al Ismaili F, Al Khawaja H, Altarescu G, et al. The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease. Mol Genet Genomic Med. 2021;9(5):e1666.PubMedPubMedCentralCrossRef Germain DP, Moiseev S, Suarez-Obando F, Al Ismaili F, Al Khawaja H, Altarescu G, et al. The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease. Mol Genet Genomic Med. 2021;9(5):e1666.PubMedPubMedCentralCrossRef
89.
go back to reference Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry. Genet Med. 2013;15(12):958–65.PubMedCrossRef Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry registry. Genet Med. 2013;15(12):958–65.PubMedCrossRef
90.
go back to reference Tower-Rader A, Jaber WA. Multimodality imaging assessment of Fabry disease. Circ Cardiovasc Imaging. 2019;12(11):e009013.PubMedCrossRef Tower-Rader A, Jaber WA. Multimodality imaging assessment of Fabry disease. Circ Cardiovasc Imaging. 2019;12(11):e009013.PubMedCrossRef
91.
go back to reference Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase a activity. Eur Heart J. 2010;31(9):1088–97.PubMedPubMedCentralCrossRef Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase a activity. Eur Heart J. 2010;31(9):1088–97.PubMedPubMedCentralCrossRef
92.
go back to reference Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later Onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68(23):2554–63.PubMedCrossRef Hsu TR, Hung SC, Chang FP, Yu WC, Sung SH, Hsu CL, et al. Later Onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation. J Am Coll Cardiol. 2016;68(23):2554–63.PubMedCrossRef
93.
go back to reference Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.PubMedPubMedCentralCrossRef Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.PubMedPubMedCentralCrossRef
94.
go back to reference Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, et al. Myocardial Storage, Inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging. 2019;12(12):e009430.PubMedPubMedCentralCrossRef Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G, et al. Myocardial Storage, Inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging. 2019;12(12):e009430.PubMedPubMedCentralCrossRef
95.
go back to reference Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, et al. Proposed stages of myocardial phenotype development in fabry disease. JACC Cardiovasc Imaging. 2019;12(8 Pt 2):1673–83.PubMedCrossRef Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, et al. Proposed stages of myocardial phenotype development in fabry disease. JACC Cardiovasc Imaging. 2019;12(8 Pt 2):1673–83.PubMedCrossRef
96.
go back to reference Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, et al. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68(15):1707–8.PubMedCrossRef Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, et al. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68(15):1707–8.PubMedCrossRef
97.
go back to reference Nordin S, Kozor R, Baig S, Abdel-Gadir A, Medina-Menacho K, Rosmini S, et al. Cardiac phenotype of prehypertrophic Fabry disease. Circ Cardiovasc Imaging. 2018;11(6):e007168.PubMedPubMedCentralCrossRef Nordin S, Kozor R, Baig S, Abdel-Gadir A, Medina-Menacho K, Rosmini S, et al. Cardiac phenotype of prehypertrophic Fabry disease. Circ Cardiovasc Imaging. 2018;11(6):e007168.PubMedPubMedCentralCrossRef
98.
go back to reference Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601.PubMedCrossRef Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601.PubMedCrossRef
99.
go back to reference Weidemann F, Beer M, Kralewski M, Siwy J, Kampmann C. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Mol Genet Metab. 2019;126(2):169–82.PubMedCrossRef Weidemann F, Beer M, Kralewski M, Siwy J, Kampmann C. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Mol Genet Metab. 2019;126(2):169–82.PubMedCrossRef
100.
go back to reference Kramer J, Niemann M, Stork S, Frantz S, Beer M, Ertl G, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114(6):895–900.PubMedCrossRef Kramer J, Niemann M, Stork S, Frantz S, Beer M, Ertl G, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114(6):895–900.PubMedCrossRef
101.
go back to reference Hagege A, Reant P, Habib G, Damy T, Barone-Rochette G, Soulat G, et al. Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis. 2019;112(4):278–87.PubMedCrossRef Hagege A, Reant P, Habib G, Damy T, Barone-Rochette G, Soulat G, et al. Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis. 2019;112(4):278–87.PubMedCrossRef
102.
go back to reference Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med. 2020;21(3):321–38.PubMedCrossRef Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med. 2020;21(3):321–38.PubMedCrossRef
103.
go back to reference Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in cardiac and pulmonary sarcoidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76(16):1878–901.PubMedPubMedCentralCrossRef Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in cardiac and pulmonary sarcoidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76(16):1878–901.PubMedPubMedCentralCrossRef
104.
go back to reference Tadic M, Cuspidi C, Saeed S, Milojevic B, Milojevic IG. The role of cardiac magnetic resonance in diagnosis of cardiac sarcoidosis. Heart Fail Rev. 2021;26(3):653–60.PubMedCrossRef Tadic M, Cuspidi C, Saeed S, Milojevic B, Milojevic IG. The role of cardiac magnetic resonance in diagnosis of cardiac sarcoidosis. Heart Fail Rev. 2021;26(3):653–60.PubMedCrossRef
105.
106.
go back to reference Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24(5):1741–58.PubMedCrossRef Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, et al. Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24(5):1741–58.PubMedCrossRef
107.
go back to reference Okada DR, Saad E, Wand AL, Griffin JM, Kasper EK, Chen EH, et al. Effect of corticosteroid dose and duration on 18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2020;13(5):1280–2.PubMedCrossRef Okada DR, Saad E, Wand AL, Griffin JM, Kasper EK, Chen EH, et al. Effect of corticosteroid dose and duration on 18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2020;13(5):1280–2.PubMedCrossRef
108.
go back to reference Ning N, Guo HH, Iagaru A, Mittra E, Fowler M, Witteles R. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J Card Fail. 2019;25(4):307–11.PubMedCrossRef Ning N, Guo HH, Iagaru A, Mittra E, Fowler M, Witteles R. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J Card Fail. 2019;25(4):307–11.PubMedCrossRef
110.
go back to reference Amano Y, Tachi M, Tani H, Mizuno K, Kobayashi Y, Kumita S. T2-weighted cardiac magnetic resonance imaging of edema in myocardial diseases. ScientificWorldJournal. 2012;2012:194069.PubMedPubMedCentralCrossRef Amano Y, Tachi M, Tani H, Mizuno K, Kobayashi Y, Kumita S. T2-weighted cardiac magnetic resonance imaging of edema in myocardial diseases. ScientificWorldJournal. 2012;2012:194069.PubMedPubMedCentralCrossRef
111.
go back to reference Liguori C, Farina D, Vaccher F, Ferrandino G, Bellini D, Carbone I. Myocarditis: imaging up to date. Radiologia Medica. 2020;125(11):1124–34.PubMedCrossRef Liguori C, Farina D, Vaccher F, Ferrandino G, Bellini D, Carbone I. Myocarditis: imaging up to date. Radiologia Medica. 2020;125(11):1124–34.PubMedCrossRef
112.
go back to reference Palumbo P, Cannizzaro E, Di Cesare A, Bruno F, Schicchi N, Giovagnoni A, et al. Cardiac magnetic resonance in arrhythmogenic cardiomyopathies. Radiologia Medica. 2020;125(11):1087–101.PubMedCrossRef Palumbo P, Cannizzaro E, Di Cesare A, Bruno F, Schicchi N, Giovagnoni A, et al. Cardiac magnetic resonance in arrhythmogenic cardiomyopathies. Radiologia Medica. 2020;125(11):1087–101.PubMedCrossRef
113.
go back to reference Bravo PE, Raghu G, Rosenthal DG, Elman S, Petek BJ, Soine LA, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol. 2017;241:457–62.PubMedPubMedCentralCrossRef Bravo PE, Raghu G, Rosenthal DG, Elman S, Petek BJ, Soine LA, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol. 2017;241:457–62.PubMedPubMedCentralCrossRef
114.
go back to reference Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology. 2017;285(1):63–72.PubMedCrossRef Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology. 2017;285(1):63–72.PubMedCrossRef
115.
go back to reference Pradella S, Grazzini G, Brandani M, Calistri L, Nardi C, Mori F, et al. Cardiac magnetic resonance in patients with mitral valve prolapse: focus on late gadolinium enhancement and T1 mapping. Eur Radiol. 2019;29(3):1546–54.PubMedCrossRef Pradella S, Grazzini G, Brandani M, Calistri L, Nardi C, Mori F, et al. Cardiac magnetic resonance in patients with mitral valve prolapse: focus on late gadolinium enhancement and T1 mapping. Eur Radiol. 2019;29(3):1546–54.PubMedCrossRef
116.
go back to reference Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11.PubMedCrossRef Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–11.PubMedCrossRef
117.
go back to reference Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109–12.PubMedPubMedCentralCrossRef Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109–12.PubMedPubMedCentralCrossRef
118.
go back to reference Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64(6):1148–50.PubMedCrossRef Crouser ED, Ruden E, Julian MW, Raman SV. Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med. 2016;64(6):1148–50.PubMedCrossRef
119.
go back to reference Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124(20):2253–63.PubMedCrossRef Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124(20):2253–63.PubMedCrossRef
120.
go back to reference Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10:1180–93.PubMedPubMedCentralCrossRef Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10:1180–93.PubMedPubMedCentralCrossRef
121.
go back to reference Belem LC, Souza CA, Souza AS Jr, Escuissato DL, Hochhegger B, Nobre LF, et al. Metastatic pulmonary calcification: high-resolution computed tomography findings in 23 cases. Radiol Bras. 2017;50(4):231–6.PubMedPubMedCentralCrossRef Belem LC, Souza CA, Souza AS Jr, Escuissato DL, Hochhegger B, Nobre LF, et al. Metastatic pulmonary calcification: high-resolution computed tomography findings in 23 cases. Radiol Bras. 2017;50(4):231–6.PubMedPubMedCentralCrossRef
122.
go back to reference Enemark A, Jonsson ALM, Kronborg-White S, Bendstrup E. Pulmonary alveolar microlithiasis-a review. Yale J Biol Med. 2021;94(4):637–44.PubMedPubMedCentral Enemark A, Jonsson ALM, Kronborg-White S, Bendstrup E. Pulmonary alveolar microlithiasis-a review. Yale J Biol Med. 2021;94(4):637–44.PubMedPubMedCentral
123.
go back to reference Crain MA, Lakhani DA, Balar AB, Hogg JP, Adelanwa A, Hailemichael E. Tracheobronchial amyloidosis: a case report and review of literature. Radiol Case Rep. 2021;16(9):2399–403.PubMedPubMedCentralCrossRef Crain MA, Lakhani DA, Balar AB, Hogg JP, Adelanwa A, Hailemichael E. Tracheobronchial amyloidosis: a case report and review of literature. Radiol Case Rep. 2021;16(9):2399–403.PubMedPubMedCentralCrossRef
124.
go back to reference Moroni C, Bindi A, Cavigli E, Cozzi D, Luvara S, Smorchkova O, et al. CT findings of non-neoplastic central airways diseases. Jpn J Radiol. 2022;40(2):107–19.PubMedCrossRef Moroni C, Bindi A, Cavigli E, Cozzi D, Luvara S, Smorchkova O, et al. CT findings of non-neoplastic central airways diseases. Jpn J Radiol. 2022;40(2):107–19.PubMedCrossRef
125.
go back to reference Brandelik SC, Heussel CP, Kauczor HU, Rocken C, Huber L, Basset M, et al. CT features in amyloidosis of the respiratory system - Comprehensive analysis in a tertiary referral center cohort. Eur J Radiol. 2020;129:109123.PubMedCrossRef Brandelik SC, Heussel CP, Kauczor HU, Rocken C, Huber L, Basset M, et al. CT features in amyloidosis of the respiratory system - Comprehensive analysis in a tertiary referral center cohort. Eur J Radiol. 2020;129:109123.PubMedCrossRef
126.
go back to reference Caruso D, Polici M, Zerunian M, Pucciarelli F, Polidori T, Guido G, et al. Quantitative Chest CT analysis in discriminating COVID-19 from non-COVID-19 patients. Radiologia Medica. 2021;126(2):243–9.PubMedCrossRef Caruso D, Polici M, Zerunian M, Pucciarelli F, Polidori T, Guido G, et al. Quantitative Chest CT analysis in discriminating COVID-19 from non-COVID-19 patients. Radiologia Medica. 2021;126(2):243–9.PubMedCrossRef
127.
go back to reference Akira M, Inoue Y, Arai T, Sugimoto C, Tokura S, Nakata K, et al. Pulmonary fibrosis on high-resolution CT of patients with pulmonary alveolar proteinosis. AJR Am J Roentgenol. 2016;207(3):544–51.PubMedCrossRef Akira M, Inoue Y, Arai T, Sugimoto C, Tokura S, Nakata K, et al. Pulmonary fibrosis on high-resolution CT of patients with pulmonary alveolar proteinosis. AJR Am J Roentgenol. 2016;207(3):544–51.PubMedCrossRef
128.
go back to reference Cozzi D, Cavigli E, Moroni C, Smorchkova O, Zantonelli G, Pradella S, et al. Ground-glass opacity (GGO): a review of the differential diagnosis in the era of COVID-19. Jpn J Radiol. 2021;39(8):721–32.PubMedPubMedCentralCrossRef Cozzi D, Cavigli E, Moroni C, Smorchkova O, Zantonelli G, Pradella S, et al. Ground-glass opacity (GGO): a review of the differential diagnosis in the era of COVID-19. Jpn J Radiol. 2021;39(8):721–32.PubMedPubMedCentralCrossRef
129.
go back to reference Parker EI, Xing M, Moreno-De-Luca A, Harmouche E, Terk MR. Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders. Br J Radiol. 2014;87(1033):20130467.PubMedCrossRef Parker EI, Xing M, Moreno-De-Luca A, Harmouche E, Terk MR. Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders. Br J Radiol. 2014;87(1033):20130467.PubMedCrossRef
130.
go back to reference Wilmer MJ, Emma F, Levtchenko EN. The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol. 2010;299(5):F905–16.PubMedCrossRef Wilmer MJ, Emma F, Levtchenko EN. The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol. 2010;299(5):F905–16.PubMedCrossRef
131.
go back to reference Ciccarese F, Brandi N, Corcioni B, Golfieri R, Gaudiano C. Complicated pyelonephritis associated with chronic renal stone disease. Radiologia Medica. 2021;126(4):505–16.PubMedCrossRef Ciccarese F, Brandi N, Corcioni B, Golfieri R, Gaudiano C. Complicated pyelonephritis associated with chronic renal stone disease. Radiologia Medica. 2021;126(4):505–16.PubMedCrossRef
133.
go back to reference Chan B, Adam DN. A review of fabry disease. Skin Therapy Lett. 2018;23(2):4–6.PubMed Chan B, Adam DN. A review of fabry disease. Skin Therapy Lett. 2018;23(2):4–6.PubMed
135.
go back to reference Han JH, Ahn JH, Kim JS. Magnetic resonance elastography for evaluation of renal parenchyma in chronic kidney disease: a pilot study. Radiol Med. 2020;125(12):1209–15.PubMedCrossRef Han JH, Ahn JH, Kim JS. Magnetic resonance elastography for evaluation of renal parenchyma in chronic kidney disease: a pilot study. Radiol Med. 2020;125(12):1209–15.PubMedCrossRef
137.
go back to reference Schein A, Enriquez C, Coates TD, Wood JC. Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging. 2008;28(3):698–704.PubMedPubMedCentralCrossRef Schein A, Enriquez C, Coates TD, Wood JC. Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging. 2008;28(3):698–704.PubMedPubMedCentralCrossRef
138.
go back to reference Dahlqvist P, Isaksson M, Bensing S. Is Adrenal insufficiency a rare disease? Front Horm Res. 2016;46:106–14.PubMedCrossRef Dahlqvist P, Isaksson M, Bensing S. Is Adrenal insufficiency a rare disease? Front Horm Res. 2016;46:106–14.PubMedCrossRef
139.
go back to reference Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014 e1.PubMedCrossRef Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014 e1.PubMedCrossRef
140.
go back to reference Shin N, Choi JA, Choi JM, Cho ES, Kim JH, Chung JJ, et al. Sclerotic changes of cavernous hemangioma in the cirrhotic liver: long-term follow-up using dynamic contrast-enhanced computed tomography. Radiol Med. 2020;125(12):1225–32.PubMedCrossRef Shin N, Choi JA, Choi JM, Cho ES, Kim JH, Chung JJ, et al. Sclerotic changes of cavernous hemangioma in the cirrhotic liver: long-term follow-up using dynamic contrast-enhanced computed tomography. Radiol Med. 2020;125(12):1225–32.PubMedCrossRef
141.
go back to reference Gatti M, Calandri M, Bergamasco L, Darvizeh F, Grazioli L, Inchingolo R, et al. Characterization of the arterial enhancement pattern of focal liver lesions by multiple arterial phase magnetic resonance imaging: comparison between hepatocellular carcinoma and focal nodular hyperplasia. Radiol Med. 2020;125(4):348–55.PubMedCrossRef Gatti M, Calandri M, Bergamasco L, Darvizeh F, Grazioli L, Inchingolo R, et al. Characterization of the arterial enhancement pattern of focal liver lesions by multiple arterial phase magnetic resonance imaging: comparison between hepatocellular carcinoma and focal nodular hyperplasia. Radiol Med. 2020;125(4):348–55.PubMedCrossRef
142.
go back to reference Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp. 2021;5(1):52.PubMedPubMedCentralCrossRef Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp. 2021;5(1):52.PubMedPubMedCentralCrossRef
143.
go back to reference Dioguardi Burgio M, Ronot M, Reizine E, Rautou PE, Castera L, Paradis V, et al. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol. 2020;30(4):2293–301.PubMedCrossRef Dioguardi Burgio M, Ronot M, Reizine E, Rautou PE, Castera L, Paradis V, et al. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol. 2020;30(4):2293–301.PubMedCrossRef
144.
go back to reference Hirooka M, Koizumi Y, Sunago K, Nakamura Y, Hirooka K, Watanabe T, et al. Efficacy of B-mode ultrasound-based attenuation for the diagnosis of hepatic steatosis: a systematic review/meta-analysis. J Med Ultrason (2001). 2022;49(2):199–210.PubMedCrossRef Hirooka M, Koizumi Y, Sunago K, Nakamura Y, Hirooka K, Watanabe T, et al. Efficacy of B-mode ultrasound-based attenuation for the diagnosis of hepatic steatosis: a systematic review/meta-analysis. J Med Ultrason (2001). 2022;49(2):199–210.PubMedCrossRef
145.
go back to reference Argalia G, Tarantino G, Ventura C, Campioni D, Tagliati C, Guardati P, et al. Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiologia Medica. 2021;126(6):894–9.PubMedCrossRef Argalia G, Tarantino G, Ventura C, Campioni D, Tagliati C, Guardati P, et al. Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiologia Medica. 2021;126(6):894–9.PubMedCrossRef
146.
go back to reference Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416–25.PubMedCrossRef Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416–25.PubMedCrossRef
147.
go back to reference Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564–73.PubMedCrossRef Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol. 2019;29(7):3564–73.PubMedCrossRef
148.
go back to reference Hyodo T, Hori M, Lamb P, Sasaki K, Wakayama T, Chiba Y, et al. Multimaterial decomposition algorithm for the quantification of liver fat content by using fast-Kilovolt-Peak switching dual-energy CT: experimental validation. Radiology. 2017;282(2):381–9.PubMedCrossRef Hyodo T, Hori M, Lamb P, Sasaki K, Wakayama T, Chiba Y, et al. Multimaterial decomposition algorithm for the quantification of liver fat content by using fast-Kilovolt-Peak switching dual-energy CT: experimental validation. Radiology. 2017;282(2):381–9.PubMedCrossRef
149.
go back to reference Cicero G, Mazziotti S, Silipigni S, Blandino A, Cantisani V, Pergolizzi S, et al. Dual-energy CT quantification of fractional extracellular space in cirrhotic patients: comparison between early and delayed equilibrium phases and correlation with oesophageal varices. Radiologia Medica. 2021;126(6):761–7.PubMedCrossRef Cicero G, Mazziotti S, Silipigni S, Blandino A, Cantisani V, Pergolizzi S, et al. Dual-energy CT quantification of fractional extracellular space in cirrhotic patients: comparison between early and delayed equilibrium phases and correlation with oesophageal varices. Radiologia Medica. 2021;126(6):761–7.PubMedCrossRef
150.
go back to reference Bottari A, Silipigni S, Carerj ML, Cattafi A, Maimone S, Marino MA, et al. Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis. Radiol Med. 2020;125(1):7–14.PubMedCrossRef Bottari A, Silipigni S, Carerj ML, Cattafi A, Maimone S, Marino MA, et al. Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in cirrhosis. Radiol Med. 2020;125(1):7–14.PubMedCrossRef
151.
go back to reference Chen ZY, Liu YP, Zheng GJ. Computed tomography and magnetic resonance imaging features of primary and secondary hepatic glycogenosis. Ann Hepatol. 2018;17(6):903–5.PubMedCrossRef Chen ZY, Liu YP, Zheng GJ. Computed tomography and magnetic resonance imaging features of primary and secondary hepatic glycogenosis. Ann Hepatol. 2018;17(6):903–5.PubMedCrossRef
152.
go back to reference Vernuccio F, Austin S, Meyer M, Guy CD, Kishnani PS, Marin D. “Bull’s eye” appearance of hepatocellular adenomas in patients with glycogen storage disease type I-atypical magnetic resonance imaging findings: two case reports. World J Clin Cases. 2021;9(4):871–7.PubMedPubMedCentralCrossRef Vernuccio F, Austin S, Meyer M, Guy CD, Kishnani PS, Marin D. “Bull’s eye” appearance of hepatocellular adenomas in patients with glycogen storage disease type I-atypical magnetic resonance imaging findings: two case reports. World J Clin Cases. 2021;9(4):871–7.PubMedPubMedCentralCrossRef
153.
go back to reference Li J, Cao B, Bi X, Chen W, Wang L, Du Z, et al. Evaluation of liver function in patients with chronic hepatitis B using Gd-EOB-DTPA-enhanced T1 mapping at different acquisition time points: a feasibility study. Radiologia Medica. 2021;126(9):1149–58.PubMedCrossRef Li J, Cao B, Bi X, Chen W, Wang L, Du Z, et al. Evaluation of liver function in patients with chronic hepatitis B using Gd-EOB-DTPA-enhanced T1 mapping at different acquisition time points: a feasibility study. Radiologia Medica. 2021;126(9):1149–58.PubMedCrossRef
154.
go back to reference Werner S, Krauss B, Haberland U, Bongers M, Starke U, Bakchoul T, et al. Dual-energy CT for liver iron quantification in patients with haematological disorders. Eur Radiol. 2019;29(6):2868–77.PubMedCrossRef Werner S, Krauss B, Haberland U, Bongers M, Starke U, Bakchoul T, et al. Dual-energy CT for liver iron quantification in patients with haematological disorders. Eur Radiol. 2019;29(6):2868–77.PubMedCrossRef
155.
go back to reference Cicero G, Ascenti G, Albrecht MH, Blandino A, Cavallaro M, D’Angelo T, et al. Extra-abdominal dual-energy CT applications: a comprehensive overview. Radiol Med. 2020;125(4):384–97.PubMedCrossRef Cicero G, Ascenti G, Albrecht MH, Blandino A, Cavallaro M, D’Angelo T, et al. Extra-abdominal dual-energy CT applications: a comprehensive overview. Radiol Med. 2020;125(4):384–97.PubMedCrossRef
156.
go back to reference Dohan A, Vargas O, Dautry R, Guerrache Y, Woimant F, Hamzi L, et al. MR imaging features of focal liver lesions in Wilson disease. Abdom Radiol (NY). 2016;41(9):1811–24.PubMedCrossRef Dohan A, Vargas O, Dautry R, Guerrache Y, Woimant F, Hamzi L, et al. MR imaging features of focal liver lesions in Wilson disease. Abdom Radiol (NY). 2016;41(9):1811–24.PubMedCrossRef
157.
go back to reference Ozcan HN, Haliloglu M, Sokmensuer C, Akata D, Ozmen M, Karcaaltincaba M. Imaging for abdominal involvement in amyloidosis. Diagn Interv Radiol. 2017;23(4):282–5.PubMedPubMedCentralCrossRef Ozcan HN, Haliloglu M, Sokmensuer C, Akata D, Ozmen M, Karcaaltincaba M. Imaging for abdominal involvement in amyloidosis. Diagn Interv Radiol. 2017;23(4):282–5.PubMedPubMedCentralCrossRef
158.
160.
go back to reference Higashi M, Tanabe M, Okada M, Furukawa M, Iida E, Ito K. Influence of fat deposition on T1 mapping of the pancreas: evaluation by dual-flip-angle MR imaging with and without fat suppression. Radiol Med. 2020;125(1):1–6.PubMedCrossRef Higashi M, Tanabe M, Okada M, Furukawa M, Iida E, Ito K. Influence of fat deposition on T1 mapping of the pancreas: evaluation by dual-flip-angle MR imaging with and without fat suppression. Radiol Med. 2020;125(1):1–6.PubMedCrossRef
161.
go back to reference Harrington KA, Shukla-Dave A, Paudyal R, Do RKG. MRI of the pancreas. J Magn Reson Imaging. 2021;53(2):347–59.PubMedCrossRef Harrington KA, Shukla-Dave A, Paudyal R, Do RKG. MRI of the pancreas. J Magn Reson Imaging. 2021;53(2):347–59.PubMedCrossRef
163.
go back to reference Brizi MG, Perillo F, Cannone F, Tuzza L, Manfredi R. The role of imaging in acute pancreatitis. Radiologia Medica. 2021;126(8):1017–29.PubMedCrossRef Brizi MG, Perillo F, Cannone F, Tuzza L, Manfredi R. The role of imaging in acute pancreatitis. Radiologia Medica. 2021;126(8):1017–29.PubMedCrossRef
164.
165.
go back to reference Sequeiros IM, Hester K, Callaway M, Williams A, Garland Z, Powell T, et al. MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients. Br J Radiol. 2010;83(995):921–6.PubMedPubMedCentralCrossRef Sequeiros IM, Hester K, Callaway M, Williams A, Garland Z, Powell T, et al. MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients. Br J Radiol. 2010;83(995):921–6.PubMedPubMedCentralCrossRef
166.
go back to reference Pfeifer CD, Schoennagel BP, Grosse R, Wang ZJ, Graessner J, Nielsen P, et al. Pancreatic iron and fat assessment by MRI-R2* in patients with iron overload diseases. J Magn Reson Imaging. 2015;42(1):196–203.PubMedCrossRef Pfeifer CD, Schoennagel BP, Grosse R, Wang ZJ, Graessner J, Nielsen P, et al. Pancreatic iron and fat assessment by MRI-R2* in patients with iron overload diseases. J Magn Reson Imaging. 2015;42(1):196–203.PubMedCrossRef
167.
go back to reference Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348–54.PubMedCrossRef Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes. 2002;51(8):2348–54.PubMedCrossRef
168.
go back to reference Crane GM, Liu YC, Chadburn A. Spleen: development, anatomy and reactive lymphoid proliferations. Semin Diagn Pathol. 2021;38(2):112–24.PubMedCrossRef Crane GM, Liu YC, Chadburn A. Spleen: development, anatomy and reactive lymphoid proliferations. Semin Diagn Pathol. 2021;38(2):112–24.PubMedCrossRef
169.
go back to reference Aslan E, Luo JW, Lesage A, Paquin P, Cerny M, Chin AS, et al. MRI-based R2* mapping in patients with suspected or known iron overload. Abdom Radiol (NY). 2021;46(6):2505–15.PubMedCrossRef Aslan E, Luo JW, Lesage A, Paquin P, Cerny M, Chin AS, et al. MRI-based R2* mapping in patients with suspected or known iron overload. Abdom Radiol (NY). 2021;46(6):2505–15.PubMedCrossRef
170.
go back to reference Abdel Razek AAK, Barakat T, Ali K. Assessment of liver and spleen in children with gaucher disease type 1 with chemical shift imaging. J Comput Assist Tomogr. 2019;43(2):183–6.PubMedCrossRef Abdel Razek AAK, Barakat T, Ali K. Assessment of liver and spleen in children with gaucher disease type 1 with chemical shift imaging. J Comput Assist Tomogr. 2019;43(2):183–6.PubMedCrossRef
171.
go back to reference Lama N, Briasoulis A, Karavasilis E, Stamatelopoulos K, Chasouraki A, Alexopoulou E, et al. The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Imaging. 2022;13(1):55.PubMedPubMedCentralCrossRef Lama N, Briasoulis A, Karavasilis E, Stamatelopoulos K, Chasouraki A, Alexopoulou E, et al. The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Imaging. 2022;13(1):55.PubMedPubMedCentralCrossRef
172.
go back to reference Shetty AS, Sipe AL, Zulfiqar M, Tsai R, Raptis DA, Raptis CA, et al. In-phase and opposed-phase imaging: applications of chemical shift and magnetic susceptibility in the chest and abdomen. Radiographics. 2019;39(1):115–35.PubMedCrossRef Shetty AS, Sipe AL, Zulfiqar M, Tsai R, Raptis DA, Raptis CA, et al. In-phase and opposed-phase imaging: applications of chemical shift and magnetic susceptibility in the chest and abdomen. Radiographics. 2019;39(1):115–35.PubMedCrossRef
173.
go back to reference Razek AAKA, Abdalla A, Barakat T, El-Taher H, Ali K. Assessment of the liver and spleen in children with Gaucher disease type I with diffusion-weighted MR imaging. Blood Cells Mol Dis. 2018;68:139–42.PubMedCrossRef Razek AAKA, Abdalla A, Barakat T, El-Taher H, Ali K. Assessment of the liver and spleen in children with Gaucher disease type I with diffusion-weighted MR imaging. Blood Cells Mol Dis. 2018;68:139–42.PubMedCrossRef
174.
go back to reference Chang CY, Rosenthal DI, Mitchell DM, Handa A, Kattapuram SV, Huang AJ. Imaging findings of metabolic bone disease. Radiographics. 2016;36(6):1871–87.PubMedCrossRef Chang CY, Rosenthal DI, Mitchell DM, Handa A, Kattapuram SV, Huang AJ. Imaging findings of metabolic bone disease. Radiographics. 2016;36(6):1871–87.PubMedCrossRef
175.
go back to reference Chiarilli MG, Delli Pizzi A, Mastrodicasa D, Febo MP, Cardinali B, Consorte B, et al. Bone marrow magnetic resonance imaging: physiologic and pathologic findings that radiologist should know. Radiologia Medica. 2021;126(2):264–76.PubMedCrossRef Chiarilli MG, Delli Pizzi A, Mastrodicasa D, Febo MP, Cardinali B, Consorte B, et al. Bone marrow magnetic resonance imaging: physiologic and pathologic findings that radiologist should know. Radiologia Medica. 2021;126(2):264–76.PubMedCrossRef
176.
go back to reference Adela A, Rangarajan L. Computational techniques to segment and classify lumbar compression fractures. Radiol Med. 2020;125(6):551–60.CrossRef Adela A, Rangarajan L. Computational techniques to segment and classify lumbar compression fractures. Radiol Med. 2020;125(6):551–60.CrossRef
177.
go back to reference Jimenez-Pastor A, Alberich-Bayarri A, Fos-Guarinos B, Garcia-Castro F, Garcia-Juan D, Glocker B, et al. Automated vertebrae localization and identification by decision forests and image-based refinement on real-world CT data. Radiol Med. 2020;125(1):48–56.PubMedCrossRef Jimenez-Pastor A, Alberich-Bayarri A, Fos-Guarinos B, Garcia-Castro F, Garcia-Juan D, Glocker B, et al. Automated vertebrae localization and identification by decision forests and image-based refinement on real-world CT data. Radiol Med. 2020;125(1):48–56.PubMedCrossRef
178.
go back to reference Guglielmi G, Muscarella S, Bazzocchi A. Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics. 2011;31(5):1343–64.PubMedCrossRef Guglielmi G, Muscarella S, Bazzocchi A. Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics. 2011;31(5):1343–64.PubMedCrossRef
179.
go back to reference Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.PubMedCrossRef Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.PubMedCrossRef
180.
go back to reference Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–21.PubMedCrossRef Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone. 2008;43(6):1115–21.PubMedCrossRef
181.
go back to reference Momeni M, Asadzadeh M, Mowla K, Hanafi MG, Gharibvand MM, Sahraeizadeh A. Sensitivity and specificity assessment of DWI and ADC for the diagnosis of osteoporosis in postmenopausal patients. Radiol Med. 2020;125(1):68–74.PubMedCrossRef Momeni M, Asadzadeh M, Mowla K, Hanafi MG, Gharibvand MM, Sahraeizadeh A. Sensitivity and specificity assessment of DWI and ADC for the diagnosis of osteoporosis in postmenopausal patients. Radiol Med. 2020;125(1):68–74.PubMedCrossRef
182.
go back to reference Messina C, Maffi G, Vitale JA, Ulivieri FM, Guglielmi G, Sconfienza LM. Diagnostic imaging of osteoporosis and sarcopenia: a narrative review. Quant Imaging Med Surg. 2018;8(1):86–99.PubMedPubMedCentralCrossRef Messina C, Maffi G, Vitale JA, Ulivieri FM, Guglielmi G, Sconfienza LM. Diagnostic imaging of osteoporosis and sarcopenia: a narrative review. Quant Imaging Med Surg. 2018;8(1):86–99.PubMedPubMedCentralCrossRef
183.
go back to reference Messina C, Piodi LP, Rinaudo L, Buonomenna C, Sconfienza LM, Vergani L, et al. Reproducibility of DXA-based bone strain index and the influence of body mass: an in vivo study. Radiol Med. 2020;125(3):313–8.PubMedCrossRef Messina C, Piodi LP, Rinaudo L, Buonomenna C, Sconfienza LM, Vergani L, et al. Reproducibility of DXA-based bone strain index and the influence of body mass: an in vivo study. Radiol Med. 2020;125(3):313–8.PubMedCrossRef
184.
go back to reference Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.PubMedCrossRef Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.PubMedCrossRef
185.
go back to reference Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017;28(10):2781–90.PubMedCrossRef Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017;28(10):2781–90.PubMedCrossRef
186.
go back to reference Vitale JA, Messina C, Albano D, Fascio E, Galbusera F, Corbetta S, et al. Appendicular muscle mass, thigh intermuscular fat infiltration, and risk of fall in postmenopausal osteoporotic elder women. Gerontology. 2021;67(4):415–24.PubMedCrossRef Vitale JA, Messina C, Albano D, Fascio E, Galbusera F, Corbetta S, et al. Appendicular muscle mass, thigh intermuscular fat infiltration, and risk of fall in postmenopausal osteoporotic elder women. Gerontology. 2021;67(4):415–24.PubMedCrossRef
187.
go back to reference Petak S, Barbu CG, Yu EW, Fielding R, Mulligan K, Sabowitz B, et al. The official positions of the international society for clinical densitometry: body composition analysis reporting. J Clin Densitom. 2013;16(4):508–19.PubMedCrossRef Petak S, Barbu CG, Yu EW, Fielding R, Mulligan K, Sabowitz B, et al. The official positions of the international society for clinical densitometry: body composition analysis reporting. J Clin Densitom. 2013;16(4):508–19.PubMedCrossRef
188.
go back to reference Chianca V, Albano D, Messina C, Gitto S, Ruffo G, Guarino S, et al. Sarcopenia: imaging assessment and clinical application. Abdom Radiol (NY). 2021;23:1–2. Chianca V, Albano D, Messina C, Gitto S, Ruffo G, Guarino S, et al. Sarcopenia: imaging assessment and clinical application. Abdom Radiol (NY). 2021;23:1–2.
189.
go back to reference James RA, Singh-Grewal D, Lee SJ, McGill J, Adib N, Rheumatology AP, G. Lysosomal storage disorders: a review of the musculoskeletal features. J Paediatr Child Health. 2016;52(3):262–71.PubMedCrossRef James RA, Singh-Grewal D, Lee SJ, McGill J, Adib N, Rheumatology AP, G. Lysosomal storage disorders: a review of the musculoskeletal features. J Paediatr Child Health. 2016;52(3):262–71.PubMedCrossRef
190.
go back to reference Musumeci O, Barca E, Lamperti C, Servidei S, Comi GP, Moggio M, et al. Lipomatosis incidence and characteristics in an italian cohort of mitochondrial patients. Front Neurol. 2019;10:160.PubMedPubMedCentralCrossRef Musumeci O, Barca E, Lamperti C, Servidei S, Comi GP, Moggio M, et al. Lipomatosis incidence and characteristics in an italian cohort of mitochondrial patients. Front Neurol. 2019;10:160.PubMedPubMedCentralCrossRef
191.
go back to reference Cellina M, Gibelli D, Floridi C, Oliva G. Volumetric analysis of non-contrast magnetic resonance lymphangiography in patients affected by lower extremities primary lymphedema. Radiol Med. 2020;125(4):432–5.PubMedCrossRef Cellina M, Gibelli D, Floridi C, Oliva G. Volumetric analysis of non-contrast magnetic resonance lymphangiography in patients affected by lower extremities primary lymphedema. Radiol Med. 2020;125(4):432–5.PubMedCrossRef
192.
go back to reference Gentili F, Guerrini S, Mazzei FG, Volterrani L, Mazzei MA. MRL as one-shot examination for patients suffering from lymphedema. Radiol Med. 2020;125(8):798–9.PubMedCrossRef Gentili F, Guerrini S, Mazzei FG, Volterrani L, Mazzei MA. MRL as one-shot examination for patients suffering from lymphedema. Radiol Med. 2020;125(8):798–9.PubMedCrossRef
193.
go back to reference Cellina M, Gibelli D, Martinenghi C, Giardini D, Soresina M, Menozzi A, et al. Non-contrast magnetic resonance lymphography (NCMRL) in cancer-related secondary lymphedema: acquisition technique and imaging findings. Radiol Med. 2021;126(11):1477–86.PubMedCrossRef Cellina M, Gibelli D, Martinenghi C, Giardini D, Soresina M, Menozzi A, et al. Non-contrast magnetic resonance lymphography (NCMRL) in cancer-related secondary lymphedema: acquisition technique and imaging findings. Radiol Med. 2021;126(11):1477–86.PubMedCrossRef
194.
go back to reference Gemignani F, Pietrini V, Tagliavini F, Lechi A, Neri TM, Asinari A, et al. Fabry’s disease with familial lymphedema of the lower limbs. Case report and family study. Eur Neurol. 1979;18(2):84–90.PubMedCrossRef Gemignani F, Pietrini V, Tagliavini F, Lechi A, Neri TM, Asinari A, et al. Fabry’s disease with familial lymphedema of the lower limbs. Case report and family study. Eur Neurol. 1979;18(2):84–90.PubMedCrossRef
195.
go back to reference Bordonaro V, Ciancarella P, Ciliberti P, Curione D, Napolitano C, Santangelo TP, et al. Dynamic contrast-enhanced magnetic resonance lymphangiography in pediatric patients with central lymphatic system disorders. Radiologia Medica. 2021;126(5):737–43.PubMedCrossRef Bordonaro V, Ciancarella P, Ciliberti P, Curione D, Napolitano C, Santangelo TP, et al. Dynamic contrast-enhanced magnetic resonance lymphangiography in pediatric patients with central lymphatic system disorders. Radiologia Medica. 2021;126(5):737–43.PubMedCrossRef
196.
go back to reference Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331–7.PubMedCrossRef Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331–7.PubMedCrossRef
197.
go back to reference Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand C, et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet. 2016;89(1):5–9.PubMedCrossRef Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand C, et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet. 2016;89(1):5–9.PubMedCrossRef
198.
go back to reference Amiri M, Kuech EM, Shammas H, Wetzel G, Naim HY. The Pathobiochemistry of gastrointestinal symptoms in a patient with niemann-pick type C disease. JIMD Rep. 2016;25:25–9.PubMedCrossRef Amiri M, Kuech EM, Shammas H, Wetzel G, Naim HY. The Pathobiochemistry of gastrointestinal symptoms in a patient with niemann-pick type C disease. JIMD Rep. 2016;25:25–9.PubMedCrossRef
199.
go back to reference Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol. 2003;58(8):610–20.PubMedCrossRef Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol. 2003;58(8):610–20.PubMedCrossRef
200.
go back to reference Buda P, Wieteska-Klimczak A, Ksiazyk J, Gietka P, Smorczewska-Kiljan A, Pronicki M, et al. Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome. JIMD Rep. 2012;4:25–8.PubMedCrossRef Buda P, Wieteska-Klimczak A, Ksiazyk J, Gietka P, Smorczewska-Kiljan A, Pronicki M, et al. Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome. JIMD Rep. 2012;4:25–8.PubMedCrossRef
202.
go back to reference Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502.PubMedCrossRef Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502.PubMedCrossRef
203.
go back to reference Bryan A, Knauft RF, Burns WA. Small bowel perforation in Fabry’s disease. Ann Intern Med. 1977;86(3):315–6.PubMedCrossRef Bryan A, Knauft RF, Burns WA. Small bowel perforation in Fabry’s disease. Ann Intern Med. 1977;86(3):315–6.PubMedCrossRef
204.
go back to reference Lorusso F, Principi M, Pedote P, Pignataro P, Francavilla M, Sardaro A, et al. Prevalence and clinical significance of incidental extra-intestinal findings in MR enterography: experience of a single university centre. Radiologia Medica. 2021;126(2):181–8.PubMedCrossRef Lorusso F, Principi M, Pedote P, Pignataro P, Francavilla M, Sardaro A, et al. Prevalence and clinical significance of incidental extra-intestinal findings in MR enterography: experience of a single university centre. Radiologia Medica. 2021;126(2):181–8.PubMedCrossRef
205.
go back to reference Deniz K, Yurci A, Yagbasan A, Tekelioglu F, Gursoy S, Guven K. Colonic involvement in Fabry disease. Int J Surg Pathol. 2011;19(6):777–8.PubMedCrossRef Deniz K, Yurci A, Yagbasan A, Tekelioglu F, Gursoy S, Guven K. Colonic involvement in Fabry disease. Int J Surg Pathol. 2011;19(6):777–8.PubMedCrossRef
206.
go back to reference Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51.PubMed Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51.PubMed
208.
go back to reference Politei J, Durand C, Schenone AB, Torres A, Mukdsi J, Thurberg BL. Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases? Mol Genet Metab Rep. 2017;11:8–11.PubMedPubMedCentralCrossRef Politei J, Durand C, Schenone AB, Torres A, Mukdsi J, Thurberg BL. Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases? Mol Genet Metab Rep. 2017;11:8–11.PubMedPubMedCentralCrossRef
209.
go back to reference Kocic M, Djuricic SM, Djordjevic M, Savic D, Kecman B, Sarajlija A. Appendiceal involvement in a patient with Gaucher disease. Blood Cells Mol Dis. 2018;68:109–11.PubMedCrossRef Kocic M, Djuricic SM, Djordjevic M, Savic D, Kecman B, Sarajlija A. Appendiceal involvement in a patient with Gaucher disease. Blood Cells Mol Dis. 2018;68:109–11.PubMedCrossRef
211.
go back to reference Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, et al. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging. Radiologia Medica. 2021;126(12):1497–507.PubMedCrossRef Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, et al. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging. Radiologia Medica. 2021;126(12):1497–507.PubMedCrossRef
212.
go back to reference Trinh TD, Jones B, Fishman EK. Amyloidosis of the colon presenting as ischemic colitis: a case report and review of the literature. Gastrointest Radiol. 1991;16(2):133–6.PubMedCrossRef Trinh TD, Jones B, Fishman EK. Amyloidosis of the colon presenting as ischemic colitis: a case report and review of the literature. Gastrointest Radiol. 1991;16(2):133–6.PubMedCrossRef
213.
go back to reference Napolitano M, Munari AM, Di Leo G, Panarisi NAR, Zuin G, Fava G, et al. MR enterography grading of pediatric ileocolonic Crohn disease activity based on a single bowel segment. Radiologia Medica. 2021;126(11):1396–406.PubMedCrossRef Napolitano M, Munari AM, Di Leo G, Panarisi NAR, Zuin G, Fava G, et al. MR enterography grading of pediatric ileocolonic Crohn disease activity based on a single bowel segment. Radiologia Medica. 2021;126(11):1396–406.PubMedCrossRef
215.
go back to reference Gurgitano M, Angileri SA, Roda GM, Liguori A, Pandolfi M, Ierardi AM, et al. Interventional radiology ex-machina: impact of Artificial Intelligence on practice. Radiol Med. 2021;126(7):998–1006.PubMedPubMedCentralCrossRef Gurgitano M, Angileri SA, Roda GM, Liguori A, Pandolfi M, Ierardi AM, et al. Interventional radiology ex-machina: impact of Artificial Intelligence on practice. Radiol Med. 2021;126(7):998–1006.PubMedPubMedCentralCrossRef
216.
go back to reference Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, et al. Defining a radiomic response phenotype: a pilot study using targeted therapy in NSCLC. Sci Rep. 2016;6:33860.PubMedPubMedCentralCrossRef Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, et al. Defining a radiomic response phenotype: a pilot study using targeted therapy in NSCLC. Sci Rep. 2016;6:33860.PubMedPubMedCentralCrossRef
217.
go back to reference Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J. 2021;97(1144):110–6.PubMedCrossRef Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J. 2021;97(1144):110–6.PubMedCrossRef
218.
go back to reference Neri E, Coppola F, Miele V, Bibbolino C, Grassi R. Artificial intelligence: who is responsible for the diagnosis? Radiol Med. 2020;125(6):517–21.PubMedCrossRef Neri E, Coppola F, Miele V, Bibbolino C, Grassi R. Artificial intelligence: who is responsible for the diagnosis? Radiol Med. 2020;125(6):517–21.PubMedCrossRef
Metadata
Title
Imaging of metabolic and overload disorders in tissues and organs
Authors
Federico Bruno
Domenico Albano
Andrea Agostini
Massimo Benenati
Roberto Cannella
Damiano Caruso
Michaela Cellina
Diletta Cozzi
Ginevra Danti
Federica De Muzio
Francesco Gentili
Giuliana Giacobbe
Salvatore Gitto
Giulia Grazzini
Irene Grazzini
Carmelo Messina
Anna Palmisano
Pierpaolo Palumbo
Alessandra Bruno
Francesca Grassi
Roberta Grassi
Roberta Fusco
Vincenza Granata
Andrea Giovagnoni
Vittorio Miele
Antonio Barile
on behalf of the Young SIRM Working Group
Publication date
21-01-2023
Publisher
Springer Nature Singapore
Published in
Japanese Journal of Radiology / Issue 6/2023
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-022-01379-7

Other articles of this Issue 6/2023

Japanese Journal of Radiology 6/2023 Go to the issue